KR101485418B1 - A synthetic method of high purity mirtazapine - Google Patents

A synthetic method of high purity mirtazapine Download PDF

Info

Publication number
KR101485418B1
KR101485418B1 KR20130061219A KR20130061219A KR101485418B1 KR 101485418 B1 KR101485418 B1 KR 101485418B1 KR 20130061219 A KR20130061219 A KR 20130061219A KR 20130061219 A KR20130061219 A KR 20130061219A KR 101485418 B1 KR101485418 B1 KR 101485418B1
Authority
KR
South Korea
Prior art keywords
acid
mirtazapine
reaction
methyl
phenylpiperazin
Prior art date
Application number
KR20130061219A
Other languages
Korean (ko)
Other versions
KR20140140398A (en
Inventor
이충렬
조현창
김재기
박태종
조동옥
Original Assignee
주식회사 메디켐코리아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 메디켐코리아 filed Critical 주식회사 메디켐코리아
Priority to KR20130061219A priority Critical patent/KR101485418B1/en
Publication of KR20140140398A publication Critical patent/KR20140140398A/en
Application granted granted Critical
Publication of KR101485418B1 publication Critical patent/KR101485418B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

본 발명은 항우울제로 유용한 미르타자핀(Mirtazapine)의 제조방법에 관한 것으로, 보다 상세하게는, 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 폴리인산과 메탄술포닌산의 혼합산과 톨루엔 용매하에서 고리화반응시켜 고순도의 미르타자핀(Mirtazapine)을 합성할 수 있는 개선된 방법에 관한 것이다. 본 발명에서는 미르타자핀의 제조시 농축황산을 사용하지 않고 폴리인산과 메탄설폰산을 사용하기에 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 실온에서 10 내지 30회의 분할 첨가시 발열하는 문제와 고점도의 교반으로 인한 출발물질의 잔류문제를 해결할 수 있으며, 반응용매로 톨루엔을 사용하기에 고농도의 산에서 반응 중 생기는 타르의 생성을 방지할 수 있고, 추가적으로 부수적인 용매가 사용되지 않아 경제적이다. 또한, 반응 혼합물을 톨루엔 용매하에 알카리성으로 함으로써 염화메틸렌에 비해 온도조절이 용이하고 미르타자핀이 석출되는 문제도 해결할 수 있을 뿐만 아니라, 본 발명의 제조방법에서 사용되는 반응물질은 상업적으로 사용하기에 유리하고 반응조건도 온화하여 미르타자핀의 대량 생산에 유용하다.The present invention relates to a process for preparing mirtazapine which is useful as an antidepressant and more particularly to a process for the preparation of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- The present invention relates to an improved method for synthesizing high purity mirtazapine by cyclizing a mixed acid of methanesulfonic acid and a toluene solvent. In the present invention, 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol is reacted with polyphosphoric acid and methanesulfonic acid in the presence of concentrated sulfuric acid It is possible to solve the problem of generation of heat upon addition of 10 to 30 times of division and the problem of residual starting material due to stirring of high viscosity and the use of toluene as a reaction solvent can prevent generation of tar during reaction in a high concentration of acid, In addition, ancillary solvents are not used, which is economical. In addition, by making the reaction mixture alkaline in a toluene solvent, the temperature can be easily controlled and precipitation of mirtazapine can be solved as compared with methylene chloride, and the reaction material used in the production method of the present invention can be used for commercial use Which is advantageous for mass production of mirtazapine.

Description

고순도 미르타자핀의 제조방법{A SYNTHETIC METHOD OF HIGH PURITY MIRTAZAPINE}TECHNICAL FIELD [0001] The present invention relates to a method for producing high purity mirtazapine,

본 발명은 항우울제로 유용한 미르타자핀(Mirtazapine)의 제조방법에 관한 것으로, 보다 상세하게는, 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 폴리인산과 메탄술포닌산의 혼합산과 톨루엔 용매하에서 고리화반응시켜 고순도의 미르타자핀(Mirtazapine)을 합성할 수 있는 개선된 방법에 관한 것이다.
The present invention relates to a process for preparing mirtazapine which is useful as an antidepressant and more particularly to a process for the preparation of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- The present invention relates to an improved method for synthesizing high purity mirtazapine by cyclizing a mixed acid of methanesulfonic acid and a toluene solvent.

하기 화학식 1로 표시되는 미르타자핀(Mirtazapine)은 우울증 치료용도로서 미국 식품의약청의 승인을 받아 레메론®(Remeron®) 이라는 상품명으로 판매되는 항우울제 약품이다.
To mirtazapine (Mirtazapine) represented by formula (1) is an antidepressant drug, sold under the trade name of an antidepressant purposes Remeron) Les melons ® received approval from the US Food and Drug Administration.

[화학식 1][Chemical Formula 1]

Figure 112013047916184-pat00001

Figure 112013047916184-pat00001

미르타자핀은 공개특허 10-2009-0121270에 기술된 방법에 의해 제조될 수 있다. 상기 특허는 화학식 2로 표시되는 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 실온에서 농축황산에 점적 첨가하는 방식으로 미르타자핀을 제조하는 방법을 기술하고 있다.
Mirtazapine can be prepared by the method described in the patent document 10-2009-0121270. The patent discloses a method for producing a mirtazapine by dropwise adding 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol represented by the formula (2) to concentrated sulfuric acid at room temperature .

[화학식 2](2)

Figure 112013047916184-pat00002

Figure 112013047916184-pat00002

그러나, 농축황산을 이용하는 이 방법은 하기와 같은 문제점을 가지고 있다.
However, this method using concentrated sulfuric acid has the following problems.

① 농축황산에 장시간동안 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 실온에서 점적 첨가하는데 발열이 심하고 혼합물의 교반이 충분하지 않으며 출발물질이 용해되지 않고 뭉치는 현상이 발생하기에 산업적으로 실시하기에 문제점이 있다.
(1) 2- (4-methyl-2-phenylpiperazin-1-yl) pyridin-3-methanol is added dropwise to concentrated sulfuric acid for a long period of time at room temperature and heat generation is severe, stirring of the mixture is insufficient, There is a problem in that it is industrially carried out because a bundle phenomenon occurs.

② 2-프로판올을 추출용매로 사용하며 농축하여 용매를 제거하는데 소모성 유기용매 사용과 추출 및 결정화하는 작업이 매우 복잡한 단점이 있다.
(2) Use of consumable organic solvent and extraction and crystallization are very complicated to use 2-propanol as an extraction solvent and concentrate to remove solvent.

③ 농축황산을 사용하여 반응하고 매우 강산조건에서 탈색 및 여과를 하기에 대량생산시 생산시설의 부식문제가 발생할 수 있어서 산업적으로 생산하기에 문제점이 있다.
③ It reacts with concentrated sulfuric acid and decolorizes and filtrates in very strong acid condition. Therefore, there is a problem in industrial production because mass production can cause corrosion of production facility.

이러한 문제점을 개선하기 위해 국제 공개특허 WO 2006008302에서는 농축황산을 물에 희석해서 고리화 반응을 진행하고 80 ℃에서 반응을 종결하는데 실제 실험해 본 결과 70 ℃ 이상에서 반응시 혼합물이 진한 붉은색으로 변하고 결정화시 미르타자핀이 노란색 결정으로 얻어지는 단점이 있다. 또한 재결정 용매로 에틸아세테이트를 사용하는데 에틸아세테이트에 대한 미르타자핀의 용해도가 좋아서 수율이 현저히 떨어진다.
In order to solve these problems, WO 2006008302 discloses that diluted sulfuric acid is diluted in water to proceed the cyclization reaction, and the reaction is terminated at 80 ° C. As a result of the experiment, the mixture turns dark red upon reaction at 70 ° C. or higher There is a disadvantage in that the myrtazapine is obtained as yellow crystals upon crystallization. In addition, ethyl acetate is used as a recrystallization solvent, but the yield of the ethyl acetate is remarkably low because of the good solubility of the mirtazapine.

이상에서 살펴본 바와 같이, 농축황산 및 희석된 황산과의 반응에 따른 일반적인 미르타자핀의 제조방법은 반응제어가 어렵거나 추출 및 정제과정의 복잡함 그리고 최종제품의 색깔의 문제점들을 완전히 방지하거나 줄이는데는 한계가 있다.
As described above, the general method of producing mirtazapine according to the reaction with concentrated sulfuric acid and diluted sulfuric acid is difficult to control the reaction or complicate the extraction and purification process and completely prevent or reduce the problems of the color of the final product .

KRKR 10-2009-012127010-2009-0121270 AA WOWO 20060083022006008302 AA

본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명에서 해결하고자 하는 과제는 고순도의 미르타자핀을 고수율로 제조하는 방법을 제공하고자 하는 것이다.
SUMMARY OF THE INVENTION The present invention has been made in order to solve the problems of the prior art as described above, and it is an object of the present invention to provide a method for producing a high purity mirtazapine with high yield.

상기와 같은 과제를 해결하기 위하여, 본 발명은 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 폴리인산(Polyphosphoric acid)과 메탄설폰산(Methanesulfonic acid)의 혼합산에서 고리화반응시키는 것을 특징으로 하는 미르타자핀(Mirtazapine)의 제조 방법을 제공한다.
In order to solve the above-mentioned problems, the present invention provides a process for producing 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol from polyphosphoric acid and methanesulfonic acid And a cyclization reaction is carried out in a mixed acid. The present invention also provides a process for producing mirtazapine.

상기 혼합산은 상기 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여 폴리인산 400 내지 1000 중량부와 메탄설폰산 30 내지 300 중량부를 사용하는 것이 바람직하다.
The mixed acid is prepared by using 400 to 1000 parts by weight of polyphosphoric acid and 30 to 300 parts by weight of methanesulfonic acid per 100 parts by weight of the 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- desirable.

상기 고리화반응은 유기용매의 존재하에 진행되는 것이 바람직하다.
The cyclization reaction is preferably carried out in the presence of an organic solvent.

상기 유기용매는 톨루엔, 자일렌, 벤젠 및 클로로벤젠으로 이루어지는 군으로부터 1종 이상 선택되는 것이 바람직하다.
The organic solvent is preferably at least one selected from the group consisting of toluene, xylene, benzene and chlorobenzene.

상기 고리화반응의 반응온도는 60 내지 90℃에서 수행하는 것이 바람직하다.
The reaction temperature of the cyclization reaction is preferably 60 to 90 < 0 > C.

상기 고리화반응의 반응시간은 3 내지 8시간 동안 수행되는 것이 바람직하다.
The reaction time of the cyclization reaction is preferably 3 to 8 hours.

상기 혼합산에는 염산, 황산, 인산, 아세트산, 개미산 및 p-톨루엔설폰산으로 이루어지는 군으로부터 1종 이상의 산이 더 첨가되는 것이 바람직하다.
The mixed acid is preferably one or more acids selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, formic acid and p -toluenesulfonic acid.

본 발명에서는 미르타자핀의 제조시 농축황산을 사용하지 않고 폴리인산과 메탄설폰산을 사용하기에 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 실온에서 10 내지 30회의 분할 첨가시 발열하는 문제와 고점도의 교반으로 인한 출발물질의 잔류문제를 해결할 수 있으며, 반응용매로 톨루엔을 사용하기에 고농도의 산에서 반응 중 생기는 타르의 생성을 방지할 수 있고, 추가적으로 부수적인 용매가 사용되지 않아 경제적이다. 또한, 반응 혼합물을 톨루엔 용매하에 알카리성으로 형성함으로써 염화메틸렌에 비해 온도조절이 용이하고 미르타자핀이 석출되는 문제도 해결할 수 있을 뿐만 아니라, 본 발명의 제조방법에서 사용되는 반응물질은 상업적으로 사용하기에 유리하고 반응조건도 온화하여 미르타자핀의 대량 생산에 유용하다.
In the present invention, 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol is reacted with polyphosphoric acid and methanesulfonic acid in the presence of concentrated sulfuric acid It is possible to solve the problem of generation of heat upon addition of 10 to 30 times of division and the problem of residual starting material due to stirring of high viscosity and the use of toluene as a reaction solvent can prevent generation of tar during reaction in a high concentration of acid, In addition, ancillary solvents are not used, which is economical. In addition, by forming the reaction mixture in an alkaline state in a toluene solvent, the temperature can be easily controlled and the precipitation of mirtazapine can be solved as compared with methylene chloride, and the reaction material used in the production method of the present invention can be used for commercial use And the reaction conditions are mild, which is useful for the mass production of the mirtazapine.

도 1은 본 발명의 미르타자핀 합성에서의 반응식을 나타낸 것이다.Figure 1 shows the reaction scheme in the synthesis of the mirtazapine of the present invention.

이하, 본 발명을 상세하게 설명한다.
Hereinafter, the present invention will be described in detail.

본 발명의 발명자들은 산업적으로 이용하기에 적합하도록 반응물질의 취급이 용이하면서도 반응조건이 온화하게 유지되며, 특히 미르타자핀의 일반적인 합성법에서 문제시되는 대량생산작업의 복잡성과 최종제품의 색깔의 문제점들을 방지하면서 고순도의 미르타자핀을 효율적으로 합성하는 방법을 개발하기 위하여 연구를 거듭한 결과, 출발물질인 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 폴리인산과 메탄설폰산의 혼합산에서 고리화반응시키는 경우 위와 같은 문제점을 모두 해결할 수 있음을 확인하고 본 발명을 완성하였다.
The inventors of the present invention have found that the complexity of the mass production operation and the problems of the color of the final product, which are problematic in the general synthesis of mirtazapine, (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol as a starting material to poly It has been found that the above problems can be solved when a cyclization reaction is performed in a mixed acid of phosphoric acid and methane sulfonic acid, and the present invention has been completed.

따라서, 본 발명은 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 폴리인산(Polyphosphoric acid)과 메탄설폰산(Methanesulfonic acid)의 혼합산에서 고리화반응시키는 것을 특징으로 하는 미르타자핀(Mirtazapine)의 제조 방법을 제공한다.
Accordingly, the present invention relates to a process for the cyclization of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol in a mixed acid of polyphosphoric acid and methanesulfonic acid Wherein Mirtazapine is produced by a method comprising the steps of:

상기 혼합산은 상기 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여, 폴리인산 300 내지 1,500 중량부, 바람직하게는 400 내지 1000 중량부를 사용하며, 메탄설폰산 10 내지 500 중량부, 바람직하게는 30 내지 300 중량부를 사용할 수 있다.
The mixed acid is used in an amount of 300 to 1,500 parts by weight, preferably 400 to 1,000 parts by weight, based on 100 parts by weight of the 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- 10 to 500 parts by weight, preferably 30 to 300 parts by weight, of methane sulfonic acid can be used.

상기 고리화반응은 유기용매의 부재 또는 유기용매의 존재하에 진행될 수 있으며, 상기 유기용매는 톨루엔, 자일렌, 벤젠 및 클로로벤젠으로 이루어지는 군으로부터 1종 이상 선택되는 것이 바람직하며, 톨루엔인 것이 가장 바람직하다.
The cyclization reaction may be carried out in the absence of an organic solvent or in the presence of an organic solvent. The organic solvent is preferably at least one selected from the group consisting of toluene, xylene, benzene and chlorobenzene, and most preferably toluene Do.

상기 고리화반응의 반응온도는 통상 35 내지 120 ℃, 바람직하게는 60 내지 120 ℃, 타르상 불순물 생성 억제측면에서 더 바람직하게는 60 내지 90 ℃에서 3 내지 8 시간 동안 반응을 진행시키는 것이 바람직하다.
The reaction is preferably carried out at a reaction temperature of 35 to 120 ° C, preferably 60 to 120 ° C, more preferably 60 to 90 ° C for 3 to 8 hours in view of inhibition of tar-phase impurity formation .

상기 혼합산에는 염산, 황산, 인산, 아세트산, 개미산 및 p-톨루엔설폰산으로 이루어지는 군으로부터 1종 이상의 산이 더 첨가될 수 있다.
The mixed acid may further include at least one acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, formic acid, and p -toluenesulfonic acid.

바람직한 구체예로서, 고리화반응은 폴리인산과 메탄설폰산의 혼합산에 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 넣고 온도를 승온하여 반응을 진행시킨다. 반응온도는 60 내지 90 ℃에서 3 내지 8시간 동안 반응을 진행시키는 것이 좋다. 반응의 종료는 TLC로 확인할 수 있다. 반응 종료 후, 반응혼합물에 10 내지 50 %의 수산화나트륨 수용액을 적가하여 pH를 1 내지 2로 조절한 후 색상 개선 및 불순물 제거 측면에서 탈색을 행하는 것이 바람직하다. 탈색 및 여과한 후 수산화나트륨을 사용하여 pH를 알칼리로 조절하는데 pH는 9 내지 11이 적당하다.In a preferred embodiment, the cyclization reaction is carried out by adding 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol to a mixed acid of polyphosphoric acid and methanesulfonic acid, . The reaction is preferably carried out at 60 to 90 占 폚 for 3 to 8 hours. The end of the reaction can be confirmed by TLC. After completion of the reaction, it is preferable to add 10 to 50% aqueous solution of sodium hydroxide dropwise to the reaction mixture to adjust the pH to 1 to 2, followed by decolorization in terms of color improvement and impurity removal. After decolorization and filtration, sodium hydroxide is used to adjust the pH to alkaline pH of 9-11.

알칼리로 pH 조절시 사용되는 유기용매로는 톨루엔이 적절하며, 추출시 승온하여 미르타자핀이 석출되는 것을 방지할 수 있으며 추출시 온도는 40 내지 60 ℃가 적당하다. 톨루엔의 사용량은 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여 300 내지 1500 중량부로 사용하는 것이 바람직하며, 300 내지 700 중량부로 사용하는 것이 더 바람직하다.
Toluene is suitable as an organic solvent for adjusting the pH with an alkali. It can prevent precipitation of mirtazapine by heating at the time of extraction, and the temperature at extraction is suitably 40 to 60 ° C. The amount of toluene to be used is preferably 300 to 1500 parts by weight, more preferably 300 to 700 parts by weight, based on 100 parts by weight of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- More preferable.

추출된 유기용매층을 감압농축한 후 남아있는 유기용매를 제거하고 결정화를 용이하게 하기 위해 헵탄으로 재농축한다. 이때 사용되는 헵탄은 통상 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여 100 내지 300 중량부로 사용하는 것이 바람직하다.
The extracted organic solvent layer is concentrated under reduced pressure, and the remaining organic solvent is removed and re-concentrated with heptane to facilitate crystallization. The heptane used herein is preferably used in an amount of 100 to 300 parts by weight based on 100 parts by weight of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol.

농축완료된 미르타자핀 결정을 고순도로 제조하기 위해 2-프로판올과 헵탄으로 정제를 실시한다. 이때 사용되는 2-프로판올의 양은 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여 50 내지 500 중량부로 사용하는 것이 바람직하고, 더 바람직하게는 100 내지 300 중량부로 사용하는 것이다. 결정화를 돕기 위해 사용되는 헵탑의 양은 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여 100 내지 700 중량부로 사용하는 것이 바람직하고, 더 바람직하게는 100 내지 300 중량부로 사용하는 것이다.
Purification is carried out with 2-propanol and heptane in order to prepare the concentrated mirtazapine crystals with high purity. The amount of 2-propanol to be used is preferably 50 to 500 parts by weight based on 100 parts by weight of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol, 100 to 300 parts by weight. The amount of the heptane used for facilitating the crystallization is preferably 100 to 700 parts by weight based on 100 parts by weight of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol, Is used in an amount of 100 to 300 parts by weight.

여과 후 얻은 무수 미르타자핀 결정은 40 내지 60 ℃에서 감압건조시킬 수 있다.The anhydrous mirtazapine crystals obtained after filtration can be dried under reduced pressure at 40 to 60 ° C.

본 발명에 따른 제조방법은 상기 화학식 1로 표시되는 미르타자핀의 약제학적으로 허용 가능한 염의 제조방법을 포함할 수도 있다. 상기 미르타자핀의 약제학적으로 허용 가능한 염의 제조방법은 당 분야에서 널리 알려진 것으로 통상의 방법이기도 하다.
The preparation method according to the present invention may include a method for preparing a pharmaceutically acceptable salt of the mirtazapine represented by the above formula (1). The method for preparing the pharmaceutically acceptable salt of the mirtazapine is well known in the art and is a conventional method.

이상에서 설명한 바와 같은 본 발명은 하기의 실시예에 의거하여 더욱 상세히 설명하겠는 바, 본 발명이 이에 한정되는 것은 아니다.
The present invention will now be described in more detail with reference to the following examples, but the present invention is not limited thereto.

[[ 실시예Example ]]

분석 조건Analysis condition

하기 실시예 1 내지 실시예 4 및 비교예 1 내지 비교예 4의 미르타자핀 합성에 사용된 분석조건은 다음과 같다.
The analytical conditions used for the synthesis of the mirtazapine of Examples 1 to 4 and Comparative Examples 1 to 4 are as follows.

HPLC 분석조건 ; USP MethodHPLC analysis conditions; USP Method

분석기기 : Agilent 1260 SystemAnalytical Instruments: Agilent 1260 System

컬럼 : Capcell Pak C18 (5, 250mm X 4.6mm)Column: Capcell Pak C 18 (5, 250 mm X 4.6 mm)

이동상 : 아세토니트릴, 메탄올, 테트라히드로퓨란, 버퍼(15:12.5:7.5:65)Mobile phase: acetonitrile, methanol, tetrahydrofuran, buffer (15: 12.5: 7.5: 65)

버퍼 : 테트라메틸암모늄히드록사이드펜타하이드레이트 18g을 증류수 950mL에 용해하고 인산으로 pH 7.4로 조절한 후 증류수를 첨가하여 1L로 제조 Buffer: 18 g of tetramethylammonium hydroxide pentahydrate was dissolved in 950 ml of distilled water, adjusted to pH 7.4 with phosphoric acid, and distilled water was added thereto to prepare 1 liter

유속 : 1.5mL / minFlow rate: 1.5 mL / min

검출기 : UV 290nmDetector: UV 290 nm

컬럼온도 : 40℃
Column temperature: 40 ° C

실시예Example 1 One

반응기에 폴리인산 500g, 메탄설폰산 100g을 투입하고 50℃까지 가열한다. 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100g을 반응기에 투입하고 온도를 75℃로 유지하면서 5시간 동안 교반한다. 반응완결을 TLC로 확인하고 반응혼합물을 35℃로 냉각하고 증류수 300g을 첨가한 후 25% 수산화나트륨 수용액을 적가하여 pH를 1 내지 2로 조절한다. 층분리를 실시하고 수층에 활성탄 10g을 넣고 30분 동안 교반한다. 탈색제를 여과하고 세척은 물 10g으로 한다. 수층에 톨루엔 500g을 투입하고 온도를 60℃ 미만으로 유지하면서 25% 수산화나트륨 수용액으로 pH를 10.5 내지 11로 조절한 후 층분리를 실시한다. 유기층에 무수 황산나트륨 20g을 넣고 30분간 교반 후 여과한다. 유기층을 감압농축하고 2-프로판올 100g과 헵탄 150g을 넣고 환류하여 30분간 교반한다. 온도를 25℃로 서서히 냉각한 후 30분간 교반 후 여과한다. 세척은 헵탄 100g으로 하고 60℃에서 10시간 동안 건조하여 미르타자핀 69.8g을 얻었다. 수율은 74.5%, HPLC 순도는 99.84%였다.
500 g of polyphosphoric acid and 100 g of methanesulfonic acid are charged into the reactor and heated to 50 占 폚. 100 g of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol are put into the reactor and stirred for 5 hours while maintaining the temperature at 75 占 폚. After completion of the reaction is confirmed by TLC, the reaction mixture is cooled to 35 DEG C, 300 g of distilled water is added, and then a 25% aqueous sodium hydroxide solution is added dropwise to adjust the pH to 1-2. Layer separation is carried out, and 10 g of activated carbon is added to the aqueous layer, followed by stirring for 30 minutes. Decolorant is filtered and washed with 10 g of water. 500 g of toluene was added to the aqueous layer and the pH was adjusted to 10.5 to 11 with 25% aqueous sodium hydroxide solution while maintaining the temperature at less than 60 ° C, followed by layer separation. 20 g of anhydrous sodium sulfate is added to the organic layer, which is stirred for 30 minutes and then filtered. The organic layer was concentrated under reduced pressure, 100 g of 2-propanol and 150 g of heptane were added, refluxed, and stirred for 30 minutes. The temperature is gradually lowered to 25 캜, stirred for 30 minutes, and then filtered. Washing was carried out with 100 g of heptane and drying at 60 DEG C for 10 hours to obtain 69.8 g of mirtazapine. The yield was 74.5% and the HPLC purity was 99.84%.

실시예Example 2 2

폴리인산 500g과 메탄설폰산 100g 대신 폴리인산 1kg과 메탄설폰산 50g을 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 합성하여 미르타자핀 73.2g을 얻었다. 수율은 78.2%, HPLC 순도는 99.86%였다.
Except that 500 g of polyphosphoric acid and 100 g of methanesulfonic acid were used instead of 1 kg of polyphosphoric acid and 50 g of methanesulfonic acid, 73.2 g of mirtazapine was obtained. The yield was 78.2% and the HPLC purity was 99.86%.

실시예Example 3 3

반응기에 폴리인산 500g, 메탄설폰산 100g, 톨루엔 300g을 투입하고 50℃ 까지 가열한다. 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100g을 반응기에 투입하고 온도를 65℃로 유지하면서 5시간 동안 교반한다. 반응완결을 TLC로 확인하고 반응혼합물을 35℃ 냉각하고 증류수 300g을 첨가한 후 25% 수산화나트륨 수용액을 적가하여 pH를 1 내지 2로 조절한다. 층분리를 실시하고 수층에 활성탄 10g을 넣고 30분 동안 교반한다. 탈색제를 여과하고 세척은 물 10g으로 한다. 수층에 톨루엔 500g을 투입하고 온도를 60℃ 미만으로 유지하면서 25% 수산화나트륨 수용액으로 pH를 10.5 내지 11로 조절한 후 층분리를 실시한다. 유기층에 무수 황산나트륨 20g을 넣고 30분간 교반 후 여과한다. 유기층을 감압농축하고 2-프로판올 100g과 헵탄 150g을 넣고 환류하여 30분간 교반한다. 온도를 25℃로 서서히 냉각한 후 30분간 교반 후 여과한다. 세척은 헵탄 100g으로 하고 60℃에서 10시간 동안 건조하여 미르타자핀 75.1g을 얻었다. 수율은 80.2%, HPLC 순도는 99.98%였다.
500 g of polyphosphoric acid, 100 g of methanesulfonic acid, and 300 g of toluene were charged into the reactor and heated to 50 캜. 100 g of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol was charged into the reactor and stirred for 5 hours while maintaining the temperature at 65 占 폚. The completion of the reaction is confirmed by TLC, the reaction mixture is cooled to 35 DEG C, 300 g of distilled water is added, and the pH is adjusted to 1 to 2 by adding dropwise a 25% aqueous solution of sodium hydroxide. Layer separation is carried out, and 10 g of activated carbon is added to the aqueous layer, followed by stirring for 30 minutes. Decolorant is filtered and washed with 10 g of water. 500 g of toluene was added to the aqueous layer and the pH was adjusted to 10.5 to 11 with 25% aqueous sodium hydroxide solution while maintaining the temperature at less than 60 ° C, followed by layer separation. 20 g of anhydrous sodium sulfate is added to the organic layer, which is stirred for 30 minutes and then filtered. The organic layer was concentrated under reduced pressure, 100 g of 2-propanol and 150 g of heptane were added, refluxed, and stirred for 30 minutes. The temperature is gradually lowered to 25 캜, stirred for 30 minutes, and then filtered. Washing was carried out with 100 g of heptane and drying at 60 DEG C for 10 hours to obtain 75.1 g of mirtazapine. The yield was 80.2% and the HPLC purity was 99.98%.

실시예Example 4 4

폴리인산 500g, 메탄설폰산 100g, 톨루엔 300g 대신 폴리인산 1kg, 메탄설폰산 50g, 톨루엔 500g을 사용한 것을 제외하고는 실시예 3과 동일한 방법으로 합성하여 미르타자핀 77.2g을 얻었다. 수율은 82.4%, HPLC 순도는 99.98%였다.
Except that 500 g of polyphosphoric acid, 100 g of methanesulfonic acid and 300 g of toluene were used instead of 1 kg of polyphosphoric acid, 50 g of methane sulfonic acid and 500 g of toluene, to obtain 77.2 g of mirtazapine. The yield was 82.4% and the HPLC purity was 99.98%.

비교예Comparative Example 1 One

공개특허 10-2009-0121270의 실시예 3 방법으로 미르타자핀을 제조하였다. 이를 구체적으로 설명하면, 약 40℃에서 98% 황산 102g에 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 28.3g을 약 4시간 동안 분할하여 첨가하고, 동온도에서 12시간 동안 교반하였다. 물 204g을 반응액에 적하하고 25% 수산화나트륨 수용액을 적가하여 pH를 1 내지 2로 조정하였다. 활성탄 10g을 가하고 30℃에서 40분간 교반한 후 여과하여 물 54g으로 세정하였다. 여액에 2-프로판올 37g을 가하고 30℃에서 25% 수산화나트륨 수용액을 적하하여 pH 11로 조절한 후 헵탄 57g을 가하고 70℃로 승온하여 층분리하였다. 유기층에 2-프로판올 100g, 헵탄 15g을 가하고 활성탄 2g을 가하고, 30℃에서 30분간 교반하였다. 탈색제를 여과하고 2-프로판올 14g으로 세정하였다. 여과액을 상압하에서 농축무게가 40g이 될 때 까지 농축하였다. 약 53℃에서 미르타자핀의 종결정을 소량 가하고, 2시간 숙성시키고 1℃까지 냉각하였다. 결정을 여과하고 헵탄 14g으로 결정을 세정하였다. 약 60℃에서 감압 건조하여 옅은노란색 결정의 미르타자핀 18.0g을 얻었다. 수율은 68.0%, HPLC 순도는 99.72%였다.
Mirtazapine was prepared by the method in Example 3 of Patent Document 10-2009-0121270. Specifically, 28.3 g of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridin-3-methanol was added portionwise over about 4 hours to 102 g of 98% sulfuric acid at about 40 ° C, And the mixture was stirred at the temperature for 12 hours. 204 g of water was added dropwise to the reaction solution, and a pH of 1 to 2 was adjusted by adding dropwise a 25% aqueous solution of sodium hydroxide. 10 g of activated carbon was added, stirred at 30 ° C for 40 minutes, filtered, and washed with 54 g of water. To the filtrate, 37 g of 2-propanol was added, and a 25% aqueous sodium hydroxide solution was added dropwise at 30 ° C to adjust the pH to 11. Then, 57 g of heptane was added and the mixture was heated to 70 ° C to separate the layers. To the organic layer were added 100 g of 2-propanol and 15 g of heptane, 2 g of activated carbon was added, and the mixture was stirred at 30 캜 for 30 minutes. The decolorant was filtered and washed with 14 g of 2-propanol. The filtrate was concentrated under atmospheric pressure to a concentration of 40 g. A small amount of seed crystals of mirtazapine was added at about 53 캜, aged for 2 hours and cooled to 1 캜. The crystals were filtered and the crystals were washed with 14 g of heptane. And dried under reduced pressure at about 60 캜 to obtain 18.0 g of a myrtazapine of pale yellow crystal. The yield was 68.0% and the HPLC purity was 99.72%.

비교예Comparative Example 2 2

WO 2006008302의 실시예 1에 기재된 방법으로 미르타자핀을 제조하였다. 이를 구체적으로 설명하면, 반응기를 약 10℃까지 냉각하고 35g의 탈염수와 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 70g을 반응기에 투입하고 온도를 80℃ 미만으로 유지하면서 322g의 황산을 첨가한다. 첨가 후, 반응혼합물을 5시간 동안 75 내지 80℃로 유지한다. 이어서 반응기의 내용물을 실온으로 냉각한 후 25℃ 미만의 온도를 유지하면서 40g의 탈염수를 가한다. 그 후, 57g의 톨루엔 및 54g의 26% 수산화암모늄 수용액을 가하여 pH를 8.9 내지 9.3으로 조절한 후 미르타자핀을 추출하고, 수층을 13g의 톨루엔으로 재추출한다. 층분리된 수층을 톨루엔 10g으로 재추출한다. 유기층을 모아서 무수 황산나트륨으로 처리한 후 여과한다. 여과액을 활성탄으로 2회 탈색 처리 후 여과한다. 톨루엔을 농축하고 에틸아세테이트 140g으로 결정화하고 여과하여 옅은노란색 결정의 미르타자핀 45.4g을 얻었다. 수율은 69.3%, HPLC 순도는 99.73%였다.
Mirtazapine was prepared by the method described in Example 1 of WO 2006008302. Specifically, the reactor was cooled to about 10 ° C., and 35 g of demineralized water and 70 g of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- 322 g of sulfuric acid is added. After addition, the reaction mixture is maintained at 75-80 < 0 > C for 5 hours. The contents of the reactor are then cooled to room temperature and 40 g of demineralized water is added while maintaining the temperature below 25 < 0 > C. Thereafter, 57 g of toluene and 54 g of 26% aqueous ammonium hydroxide solution were added to adjust the pH to 8.9 to 9.3, followed by extraction of the mirtazapine and re-extraction of the aqueous layer with 13 g of toluene. The layered aqueous layer is re-extracted with 10 g of toluene. The organic layers were collected, treated with anhydrous sodium sulfate, and filtered. The filtrate is decolorized twice with activated carbon and filtered. The toluene was concentrated, crystallized with 140 g of ethyl acetate, and filtered to obtain 45.4 g of mirtazapine as a pale yellow crystal. The yield was 69.3% and the HPLC purity was 99.73%.

비교예Comparative Example 3 3

반응기에 폴리인산 500g을 투입하고 60℃까지 가열한다. 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100g을 반응기에 투입하고 온도를 95℃로 유지하면서 8시간 동안 교반한다. 반응완결을 TLC로 확인하고 반응혼합물을 35℃로 냉각하고 증류수 300g을 첨가한 후 25% 수산화나트륨 수용액을 적가하여 pH를 1 내지 2로 조절한다. 층분리를 실시하고 수층에 활성탄 10g을 넣고 30분 동안 교반한다. 탈색제를 여과하고 세척은 물 10g으로 한다. 수층에 톨루엔 500g을 투입하고 온도를 60℃ 미만으로 유지하면서 25% 수산화나트륨 수용액으로 pH를 10.5 내지 11로 조절한 후 층분리를 실시한다. 유기층에 무수 황산나트륨 20g을 넣고 30분간 교반 후 여과한다. 유기층을 감압농축하고 2-프로판올 100g과 헵탄 150g을 넣고 환류하여 30분간 교반한다. 온도를 25℃로 서서히 냉각한 후 30분간 교반 후 여과한다. 세척은 헵탄 100g으로 하고 60℃에서 10시간 동안 건조하여 미르타자핀 64.3g을 얻었다. 수율은 68.7%, HPLC 순도는 99.79%였다.
500 g of polyphosphoric acid is added to the reactor and heated to 60 占 폚. 100 g of 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine-3-methanol are put into the reactor and stirred for 8 hours while maintaining the temperature at 95 ° C. After completion of the reaction is confirmed by TLC, the reaction mixture is cooled to 35 DEG C, 300 g of distilled water is added, and then a 25% aqueous sodium hydroxide solution is added dropwise to adjust the pH to 1-2. Layer separation is carried out, and 10 g of activated carbon is added to the aqueous layer, followed by stirring for 30 minutes. Decolorant is filtered and washed with 10 g of water. 500 g of toluene was added to the aqueous layer and the pH was adjusted to 10.5 to 11 with 25% aqueous sodium hydroxide solution while maintaining the temperature at less than 60 ° C, followed by layer separation. 20 g of anhydrous sodium sulfate is added to the organic layer, which is stirred for 30 minutes and then filtered. The organic layer was concentrated under reduced pressure, 100 g of 2-propanol and 150 g of heptane were added, refluxed, and stirred for 30 minutes. The temperature is gradually lowered to 25 캜, stirred for 30 minutes, and then filtered. Washing was carried out with 100 g of heptane and drying at 60 DEG C for 10 hours to obtain 64.3 g of mirtazapine. The yield was 68.7% and the HPLC purity was 99.79%.

비교예Comparative Example 4 4

폴리인산 500g 대신 폴리인산 1kg를 사용한 것을 제외하고는 비교예 3과 동일한 방법으로 합성하여 미르타자핀 69.1g을 얻었다. 수율은 78.3%, HPLC 순도는 99.81% 였다.
Synthesis was carried out in the same manner as in Comparative Example 3 except that 1 kg of polyphosphoric acid was used instead of 500 g of polyphosphoric acid to obtain 69.1 g of mirtazapine. The yield was 78.3% and the HPLC purity was 99.81%.

결 과result

상기 실시예 1 내지 실시예 4 및 비교예 1 내지 비교예 4로부터 합성된 미르타자핀의 수율, 순도 및 색을 다음 표 1에 정리하였다.
The yield, purity and color of the mirtazapine synthesized from Examples 1 to 4 and Comparative Examples 1 to 4 are summarized in Table 1 below.

실시예Example 반응조건(출발물질 100g 기준)Reaction conditions (based on 100 g starting material) 수율yield 순도water color 실시예 1Example 1 폴리인산 500g + 메탄설폰산 100g500 g of polyphosphoric acid + 100 g of methanesulfonic acid 74.5%74.5% 99.84%99.84% 백색White 실시예 2Example 2 폴리인산 1000g + 메탄설폰산 50gPolyphosphoric acid 1000g + methane sulfonic acid 50g 78.2%78.2% 99.86%99.86% 백색White 실시예 3Example 3 폴리인산 500g + 메탄설폰산 100g + 톨루엔 300gPolyphosphoric acid 500 g + methane sulfonic acid 100 g + toluene 300 g 80.2%80.2% 99.98%99.98% 백색White 실시예 4Example 4 폴리인산 1000g + 메탄설폰산 50g + 톨루엔 500gPolyphosphoric acid 1000 g + methane sulfonic acid 50 g + toluene 500 g 82.4%82.4% 99.98%99.98% 백색White 비교예 1Comparative Example 1 98% 황산 360g98% sulfuric acid 360 g 68.0%68.0% 99.72%99.72% 옅은노란Pale yellow 비교예 2Comparative Example 2 98% 황산 460g + 탈염수 50g98% sulfuric acid 460 g + desalted water 50 g 69.3%69.3% 99.73%99.73% 옅은노란Pale yellow 비교예 3Comparative Example 3 폴리인산 500gPolyphosphoric acid 500 g 68.7%68.7% 99.79%99.79% 미백색Whitish 비교예 4Comparative Example 4 폴리인산 1000gPolyphosphoric acid 1000 g 73.8%73.8% 99.81%99.81% 미백색Whitish

상기 표 1에서 볼 수 있는 바와 같이, 본 발명의 제조방법에 따르면 폴리인산과 메탄설폰산을 혼합산으로 사용하거나 또는 톨루엔 용매하에서 반응진행시 수율과 순도 및 색상이 가장 좋게 나타난 것을 알 수 있다.
As can be seen from the above Table 1, according to the production method of the present invention, the yield, purity and color of polyphosphoric acid and methanesulfonic acid were the best when using as a mixed acid or in a toluene solvent.

이상에서 설명한 바와 같이, 본 발명에 따른 제조방법은 폴리인산과 메탄설폰산을 혼합산으로 사용하고 반응용매를 톨루엔으로 사용함으로써, 종래 제조방법에서 고농도의 산을 사용함으로써 생산시설의 부식문제, 고점도의 교반으로 인한 출발물질의 덩어리짐 또는 잔류문제 그리고 60 ℃ 이상에서 발생하는 타르 부산물이 생성되는 문제를 해결하였다. 또한, 본 발명의 제조방법은 반응조건이 편리할 뿐만 아니라 추가적인 정제 과정 없이 연속적으로 수행하는 것이 가능하다. 따라서 본 발명의 제조방법은 고순도 미르타자핀의 대량 생산에 유용하다.
As described above, the manufacturing method according to the present invention uses a high concentration of acid in the conventional production method by using polyphosphoric acid and methanesulfonic acid as a mixed acid and using a reaction solvent as toluene, The problem of agglomeration of the starting material due to agitation of the agglomerates or residues of the agglomerates and generation of tar byproducts occurring at a temperature higher than 60 deg. Further, the production method of the present invention is not only convenient in reaction conditions, but also can be carried out continuously without further purification. Therefore, the production method of the present invention is useful for mass production of high-purity mirtazapine.

Claims (7)

2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올을 폴리인산(Polyphosphoric acid)과 메탄설폰산(Methanesulfonic acid)의 혼합산에서 고리화반응시키는 것을 특징으로 하는 미르타자핀(Mirtazapine)의 제조 방법.
The process according to claim 1, wherein the methyl (2-methyl-2-phenylpiperazin-1-yl) pyridine is subjected to a cyclization reaction in a mixed acid of polyphosphoric acid and methanesulfonic acid. Process for the preparation of mirtazapine.
제 1항에 있어서,
상기 혼합산은 상기 2-(4-메틸-2-페닐피페라진-1-일)피리딘-3-메탄올 100 중량부에 대하여 폴리인산 400 내지 1000 중량부와 메탄설폰산 30 내지 300 중량부를 사용하는 것을 특징으로 하는 미르타자핀의 제조방법.
The method according to claim 1,
The mixed acid is prepared by using 400 to 1000 parts by weight of polyphosphoric acid and 30 to 300 parts by weight of methanesulfonic acid per 100 parts by weight of the 2- (4-methyl-2-phenylpiperazin-1-yl) pyridine- Characterized in that the method comprises the steps of:
제 1항에 있어서,
상기 고리화반응은 유기용매의 존재하에 진행되는 것을 특징으로 하는 미르타자핀의 제조방법.
The method according to claim 1,
Wherein the cyclization reaction is carried out in the presence of an organic solvent.
제 3항에 있어서,
상기 유기용매는 톨루엔, 자일렌, 벤젠 및 클로로벤젠으로 이루어지는 군으로부터 1종 이상 선택되는 것을 특징으로 하는 미르타자핀의 제조방법.
The method of claim 3,
Wherein the organic solvent is at least one selected from the group consisting of toluene, xylene, benzene and chlorobenzene.
제 1항에 있어서,
상기 고리화반응의 반응온도는 60 내지 90℃에서 수행하는 것을 특징으로 하는 미르타자핀의 제조방법.
The method according to claim 1,
Wherein the cyclization reaction is carried out at a reaction temperature of 60 to 90 占 폚.
제 1항에 있어서,
상기 고리화반응의 반응시간은 3 내지 8시간 동안 수행되는 것을 특징으로 하는 미르타자핀의 제조방법.
The method according to claim 1,
Wherein the reaction time of the cyclization reaction is 3 to 8 hours.
삭제delete
KR20130061219A 2013-05-29 2013-05-29 A synthetic method of high purity mirtazapine KR101485418B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR20130061219A KR101485418B1 (en) 2013-05-29 2013-05-29 A synthetic method of high purity mirtazapine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130061219A KR101485418B1 (en) 2013-05-29 2013-05-29 A synthetic method of high purity mirtazapine

Publications (2)

Publication Number Publication Date
KR20140140398A KR20140140398A (en) 2014-12-09
KR101485418B1 true KR101485418B1 (en) 2015-01-26

Family

ID=52458281

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20130061219A KR101485418B1 (en) 2013-05-29 2013-05-29 A synthetic method of high purity mirtazapine

Country Status (1)

Country Link
KR (1) KR101485418B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017088564A (en) * 2015-11-13 2017-05-25 株式会社トクヤマ Manufacturing method of mirtazapine
KR102540021B1 (en) 2020-12-02 2023-06-07 (주)유케이케미팜 Method for preparing mirtazapine suitable for mass production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020019902A (en) * 1999-04-19 2002-03-13 추후보정 Novel synthesis and crystallization of piperazine ring-containing compounds
KR20060056315A (en) * 2003-07-10 2006-05-24 악조 노벨 엔.브이. A method for the preparation of enantiomerically pure mirtazapine
KR20070053697A (en) * 2004-07-22 2007-05-25 메디쳄 쎄.아. Improved process for the manufacture of mirtazapine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020019902A (en) * 1999-04-19 2002-03-13 추후보정 Novel synthesis and crystallization of piperazine ring-containing compounds
JP2004500324A (en) 1999-04-19 2004-01-08 テバ ファーマシューティカル インダストリーズ リミティド Novel synthesis and crystallization of piperazine ring-containing compounds
KR20060056315A (en) * 2003-07-10 2006-05-24 악조 노벨 엔.브이. A method for the preparation of enantiomerically pure mirtazapine
KR20070053697A (en) * 2004-07-22 2007-05-25 메디쳄 쎄.아. Improved process for the manufacture of mirtazapine

Also Published As

Publication number Publication date
KR20140140398A (en) 2014-12-09

Similar Documents

Publication Publication Date Title
EP1658293B1 (en) A method of preparation of oxycodone
US6348458B1 (en) Polymorphic forms of olanzapine
KR20150053816A (en) Crystalline form of tenofovir disoproxil and a process for its preparation
EP2407468B1 (en) Improved method for preparing meropenem using zinc powder
JP2011508781A (en) Method for the synthesis of tetrahydrobiopterin
WO2010140168A1 (en) Improved process for preparing temozolomide
CA2859281A1 (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
CN112062767A (en) Preparation method and intermediate of rumepilone
KR101485418B1 (en) A synthetic method of high purity mirtazapine
CN113636973A (en) Industrial preparation method of 4- (6-aminopyridine-3-yl) piperazine-1-carboxylic acid tert-butyl ester
JP5192707B2 (en) Manufacturing method of mirtazapine
EP2922833A1 (en) Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one
EP1246827B1 (en) New polymorphic forms of olanzapine
CA2815167A1 (en) A process for the preparation of pure meropenem trihydrate
CN113278021B (en) Preparation method of 1, 7-diazaspiro [3.5] nonane-7-tert-butyl formate and oxalate thereof
US8952148B2 (en) Process for the preparation of taurolidine and its intermediates thereof
CN109053585B (en) Synthetic method of triclabendazole
KR100704641B1 (en) Methods for the preparation of levofloxacin having a high purity
KR101386530B1 (en) Preparation method for 3-amino-9,13b-dihydro-1H-dibenz-[c,f]imidazo[1,5-a]-azepine hydrochloride having improved purity and yield
KR101694262B1 (en) Process for preparing crystalline forms of silodosin
WO2021043200A1 (en) Method for preparing quinazoline derivative and crystallization thereof
KR20160105557A (en) Refine Method for the preparation of high purity Olanzapine
KR20060135437A (en) A process for preparing a crystalline pantoprazole sodium sesquihydrate
CN109956958B (en) Synthesis method of 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid
AU2008298402B2 (en) Method for producing N-methacryloyl-4-cyano-3-trifluoromethylaniline

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee